Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Susan Dent, Susannah Stanway, Helena Earl, Christine Brezden-Masley, Alain Cohen-Solal, Carlo G. Tocchetti, Javid J. Moslehi, John D. Groarke, Jutta Bergler-Klein, Vincent Khoo, Li Ling Tan, Markus S. Anker, Stephan von Haehling, Christoph Maack, Radek Pudil, Ana Barac, Paaladinesh Thavendiranathan, Bonnie Ky, Tomas G. NeilanYury Belenkov, Stuart D. Rosen, Zaza Iakobishvili, Aaron L. Sverdlov, Ludhmila A. Hajjar, Ariane V.S. Macedo, Charlotte Manisty, Fortunato Ciardiello, Dimitrios Farmakis, Rudolf A. de Boer, Hadi Skouri, Thomas M. Suter, Daniela Cardinale, Ronald M. Witteles, Michael G. Fradley, Joerg Herrmann, Robert F. Cornell, Ashutosh Wechelaker, Michael J. Mauro, Dragana Milojkovic, Hugues de Lavallade, Frank Ruschitzka, Andrew J.S. Coats, Petar M. Seferovic, Ovidiu Chioncel, Thomas Thum, Johann Bauersachs, M. Sol Andres, David J. Wright, Teresa López-Fernández, Chris Plummer, Daniel Lenihan

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Fingerprint

Dive into the research topics of 'Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society'. Together they form a unique fingerprint.

Medicine & Life Sciences